Abbott Laboratories (NYSE:ABT) Downgraded by Daiwa Securities Group to Neutral

Abbott Laboratories (NYSE:ABT) was downgraded by analysts at Daiwa Securities Group from an “outperform” rating to a “neutral” rating in a research report issued on Wednesday, Marketbeat.com reports. They presently have a $92.00 price objective on the healthcare product maker’s stock. Daiwa Securities Group’s price objective would suggest a potential downside of 0.89% from the company’s previous close.

A number of other research firms have also weighed in on ABT. Wells Fargo & Company cut their target price on shares of Abbott Laboratories from $122.00 to $109.00 and set an “overweight” rating on the stock in a research note on Friday, April 17th. Sanford C. Bernstein cut their target price on shares of Abbott Laboratories from $125.00 to $110.00 and set an “outperform” rating on the stock in a research note on Friday, April 17th. Stifel Nicolaus cut their target price on shares of Abbott Laboratories from $145.00 to $120.00 and set a “buy” rating on the stock in a research note on Friday, April 17th. Evercore cut their target price on shares of Abbott Laboratories from $134.00 to $120.00 and set an “outperform” rating on the stock in a research note on Friday, April 17th. Finally, Benchmark dropped their target price on Abbott Laboratories from $145.00 to $120.00 and set a “buy” rating on the stock in a report on Friday, April 17th. Two analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating and five have issued a Hold rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $119.43.

Abbott Laboratories Stock Down 3.3%

Shares of NYSE ABT opened at $92.83 on Wednesday. The stock has a market cap of $161.67 billion, a P/E ratio of 26.00, a PEG ratio of 1.60 and a beta of 0.79. The company has a current ratio of 1.58, a quick ratio of 1.18 and a debt-to-equity ratio of 0.19. Abbott Laboratories has a 12-month low of $92.65 and a 12-month high of $139.06. The business’s fifty day simple moving average is $107.21 and its 200-day simple moving average is $118.00.

Abbott Laboratories (NYSE:ABT) last announced its quarterly earnings data on Thursday, April 16th. The healthcare product maker reported $1.15 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.14 by $0.01. The business had revenue of $11.16 billion for the quarter, compared to analysts’ expectations of $10.99 billion. Abbott Laboratories had a return on equity of 17.71% and a net margin of 13.90%.The company’s revenue for the quarter was up 7.8% compared to the same quarter last year. During the same period last year, the firm earned $1.09 earnings per share. Abbott Laboratories has set its FY 2026 guidance at 5.380-5.580 EPS and its Q2 2026 guidance at 1.250-1.310 EPS. As a group, equities analysts predict that Abbott Laboratories will post 5.53 EPS for the current fiscal year.

Insider Transactions at Abbott Laboratories

In other Abbott Laboratories news, SVP Eric Shroff sold 709 shares of the firm’s stock in a transaction dated Monday, March 2nd. The stock was sold at an average price of $115.58, for a total transaction of $81,946.22. Following the transaction, the senior vice president owned 39,164 shares of the company’s stock, valued at approximately $4,526,575.12. This trade represents a 1.78% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, EVP Mary K. Moreland sold 613 shares of the firm’s stock in a transaction dated Monday, March 2nd. The stock was sold at an average price of $115.58, for a total value of $70,850.54. Following the transaction, the executive vice president directly owned 104,291 shares in the company, valued at approximately $12,053,953.78. The trade was a 0.58% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 3,055 shares of company stock valued at $353,097 over the last ninety days. Company insiders own 0.46% of the company’s stock.

Hedge Funds Weigh In On Abbott Laboratories

Several hedge funds have recently made changes to their positions in ABT. Brighton Jones LLC grew its holdings in shares of Abbott Laboratories by 10.1% during the fourth quarter. Brighton Jones LLC now owns 51,719 shares of the healthcare product maker’s stock worth $5,850,000 after purchasing an additional 4,755 shares during the last quarter. Sivia Capital Partners LLC grew its holdings in shares of Abbott Laboratories by 3.5% during the second quarter. Sivia Capital Partners LLC now owns 4,768 shares of the healthcare product maker’s stock worth $648,000 after purchasing an additional 162 shares during the last quarter. United Bank grew its holdings in shares of Abbott Laboratories by 7.4% during the second quarter. United Bank now owns 29,004 shares of the healthcare product maker’s stock worth $3,945,000 after purchasing an additional 2,001 shares during the last quarter. Main Street Financial Solutions LLC grew its holdings in shares of Abbott Laboratories by 13.6% during the second quarter. Main Street Financial Solutions LLC now owns 11,894 shares of the healthcare product maker’s stock worth $1,618,000 after purchasing an additional 1,428 shares during the last quarter. Finally, Canada Pension Plan Investment Board raised its holdings in shares of Abbott Laboratories by 25.6% in the second quarter. Canada Pension Plan Investment Board now owns 1,435,683 shares of the healthcare product maker’s stock valued at $195,267,000 after buying an additional 292,547 shares during the last quarter. Hedge funds and other institutional investors own 75.18% of the company’s stock.

More Abbott Laboratories News

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: UBS reaffirmed a buy rating on ABT (while trimming its target), keeping analyst support that underpins a constructive view of the stock. Article Title
• Positive Sentiment: Dividend-focused coverage highlights a near?3% yield and argues the pullback could be a buy opportunity for income investors. This supports demand from dividend-seeking funds. Article Title
• Positive Sentiment: Opinion pieces urging investors to “buy the dip” and comparing ABT favorably within medical devices highlight confidence in the company’s longer-term fundamentals despite the recent pullback. Article Title
• Positive Sentiment: Coverage noting ABT trades near its 52?week low while analysts remain bullish frames the current level as potential upside from existing price targets, attracting value-oriented investors. Article Title
• Positive Sentiment: Abbott’s CancerGuard / multi?cancer early detection progress and new DETECT A outcomes add a strategic diagnostics growth narrative that could materially boost long?term revenue if commercial rollout scales. Article Title
• Neutral Sentiment: Options?market flow has shown atypical activity, which some traders interpret as a bet on near?term volatility — a signal worth monitoring but not a directional confirmation. Article Title
• Neutral Sentiment: Several brokers trimmed price targets (UBS 158?135, Argus 140?125, Leerink 119?106) but many maintained buy/overweight stances — reducing near?term upside expectations while keeping medium?term support intact. Article Title Article Title Article Title
• Negative Sentiment: Social and news summaries flagged that Q1 results beat estimates but management cut full?year guidance (mild flu season, acquisition costs), which drove the post?earnings selloff and remains the primary driver of today’s weakness. Article Title
• Negative Sentiment: Headline commentary that Barclays has “lowered expectations” adds to investor caution; cumulative PT trims and the guidance cut have weighed on sentiment and liquidity. Article Title

Abbott Laboratories Company Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.